ChromaDex/CDXC

$3.66

8.28%
-
1D1W1MYTD1YMAX

About ChromaDex

Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Ticker

CDXC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Fried

Employees

106

Headquarters

Los angeles, United States
Website
chromadex.com/default.aspx

ChromaDex Metrics

BasicAdvanced
$258M
Market cap
-
P/E ratio
-$0.05
EPS
1.95
Beta
-
Dividend rate
$258M
1.95173
$4.65
$1.25
345K
2.518
1.875
0.031
0.069
-6.54%
-12.39%
-10.08%
3.106
8.878
9.071
57.13
7.52%
69.19%
12.14%

What the Analysts think about ChromaDex

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
88.52% upside
High $8.00
Low $6.00
$3.66
Current price
$6.90
Average price target

ChromaDex Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.8% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$22M
4.74%
Net income
-$400K
-500%
Profit margin
-1.8%
-482.98%

ChromaDex Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 40%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.01
-
-$0.01
-
Expected
-$0.04
-$0.03
-$0.03
-$0.02
-$0.02
Surprise
-20%
-69.23%
-
-40%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ChromaDex stock?

ChromaDex (CDXC) has a market cap of $258M as of May 15, 2024.

What is the P/E ratio for ChromaDex stock?

The price to earnings (P/E) ratio for ChromaDex (CDXC) stock is 0 as of May 15, 2024.

Does ChromaDex stock pay dividends?

No, ChromaDex (CDXC) stock does not pay dividends to its shareholders as of May 15, 2024.

When is the next ChromaDex dividend payment date?

ChromaDex (CDXC) stock does not pay dividends to its shareholders.

What is the beta indicator for ChromaDex?

ChromaDex (CDXC) has a beta rating of 1.95. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the ChromaDex stock price target?

The target price for ChromaDex (CDXC) stock is $6.9, which is 88.52% above the current price of $3.66. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ChromaDex stock

Buy or sell ChromaDex stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing